A Roundup of Major Autoimmune Transactions in the First Half of 2025
Up to $13 billions! A Roundup of Major Autoimmune Transactions in the First Half of 2025.
Blog
2025-07-07
One receptor, two FDA-approved drugs — just how crucial is CXCR4?
In recent years, the successive approvals of two new drugs have once again brought a chemokine receptor into the spotlight. In 2023, the FDA approved Motixafortide (brand name Aphexda) in combination with long-acting G-CSF for hematopoietic stem cell mobilization in patients with multiple myeloma. Then in 2024, the FDA approved Mavorixafor (Xolremdi) for the treatment […]
CCR1: An Emerging Target for Immune Regulation and Drug Development
CCR1 (C-C motif chemokine receptor 1) is a G protein-coupled receptor (GPCR) involved in inflammatory responses and immune cell migration. In recent years, with the deepening research on immune-related diseases and the tumor microenvironment, CCR1 has gradually emerged as an important therapeutic target for autoimmune diseases, tumors, and organ fibrosis. 1. Overview of CCR1 Chemokine monomers […]
DIMA Membrane Proteins Empower Nobel Team’s Breakthrough in GPCR Drug Discovery
DIMA’s CXCR4-Nanodisc Empowers New Preprint from David Baker, which is entitled “De novo design of miniprotein agonists and antagonists targeting G protein-coupled receptors”
FLT3 | A Key Therapeutic Target in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a complex and highly heterogeneous hematologic malignancy closely associated with various cytogenetic and chromosomal abnormalities. Among them, mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are one of the most common genetic alterations. Studies have shown that approximately 25% of AML patients carry FLT3 internal tandem duplication mutations (FLT3-ITD), while about […]
Blog
2025-05-20
Dual-Payload ADCs: The Next Big Thing in the ADC Arena
Efforts to improve traditional ADCs have primarily focused on the three key components: the antibody, the linker, and the payload. Previously, we summarized the research progress in bispecific ADCs. Here, we further consolidate the pipeline updates of dual-payload ADCs.
Blog
2025-04-29
NPY Receptor Family: “New Targets” and “Old Challenges” in Disease Treatment
In the drug development efforts targeting complex diseases such as neuropsychiatric disorders, metabolic dysregulation, and cancer, the neuropeptide Y (NPY) receptor family is garnering increasing attention from researchers and pharmaceutical companies alike. As a typical subfamily of G protein-coupled receptors (GPCRs), NPY receptors not only regulate a variety of physiological processes but also play critical […]
Popular Targets in the Bispecific ADC Pipeline
At the 2025 AACR Annual Meeting, Chinese ADC drugs have emerged in various forms such as bispecific ADCs and dual-toxin ADCs, forming a unique landscape at the AACR meeting. Here, we summarize the key players and target pipelines in the bispecific ADC (BsADC) space, based on AACR data.
Blog
2025-04-25
An Invitation|Welcome to meet DIMA BIOTECH in Boston in May
DIMA BIOTECH will showcase over 5,000+ in-stock lead mAbs and 500+ in-stock Nanodisc at 2025 CAS and 2025 PEGS.
News
2025-04-25
CDH17 ADCs blooms in 2025 AACR
The 116th AACR Annual Meeting will be held from April 25 to 30, 2025, at the McCormick Place Convention Center in Chicago, USA. Among the 6,470 abstracts released for the 2025 AACR, there are 340 related to antibody-drug conjugates (ADCs), covering various types such as single-target ADCs, dual-target ADCs, and dual-payload ADCs. These involve numerous […]
Blog
2025-04-17